MedTrace Logo

A Safety and Efficacy Study to Assess OZURDEX® in Patients With Macular Oedema Secondary to Retinal Vein Occlusion (RVO)

NCT01571557 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 573

Last updated 2019-04-19

Study results available
· View outcomes & findings →

Summary

This study will evaluate the relationship between time since onset of macular oedema symptoms and the achievement of vision gain in patients prescribed OZURDEX®. All care and diagnostic procedures provided are at the discretion of the participating physicians according to their clinical judgment and local standard of medical care.

Conditions

  • Macular Edema
  • Retinal Vein Occlusion

Interventions

DRUG

dexamethasone 700 ug intravitreal implant

dexamethasone 700 ug intravitreal implant administered according to standard of care.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2014-03-31
Completion
2014-06-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01571557 on ClinicalTrials.gov